LifeMD (NASDAQ:LFMD) Issues Quarterly Earnings Results

LifeMD (NASDAQ:LFMD) issued its quarterly earnings results on Monday. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.02, Zacks reports. The business had revenue of $64.26 million during the quarter, compared to analyst estimates of $57.43 million. LifeMD updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.

LifeMD Trading Up 30.4 %

NASDAQ:LFMD opened at $5.57 on Wednesday. The firm has a market cap of $241.25 million, a P/E ratio of -8.70 and a beta of 1.50. The stock’s 50 day simple moving average is $5.65 and its 200-day simple moving average is $5.37. LifeMD has a 12-month low of $3.99 and a 12-month high of $12.88.

Insider Transactions at LifeMD

In other news, CEO Justin Schreiber sold 25,000 shares of LifeMD stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $5.19, for a total transaction of $129,750.00. Following the completion of the sale, the chief executive officer now directly owns 2,703,715 shares in the company, valued at approximately $14,032,280.85. This trade represents a 0.92 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 15.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on LFMD. Mizuho started coverage on LifeMD in a research note on Wednesday, December 4th. They set a “neutral” rating and a $7.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $15.00 price target on shares of LifeMD in a research note on Tuesday. KeyCorp dropped their price target on shares of LifeMD from $10.00 to $7.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Finally, Lake Street Capital assumed coverage on shares of LifeMD in a research report on Tuesday, December 10th. They set a “buy” rating and a $12.00 price target for the company. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $11.14.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.